Clinical Trials Logo

Aspergillosis clinical trials

View clinical trials related to Aspergillosis.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05903612 Withdrawn - Asthma Clinical Trials

Allergic Bronchopulmonary Aspergillosis Prescreening Study

Start date: January 10, 2024
Phase:
Study type: Observational

This prescreening study is being conducted to diagnose ABPA in selected patients with asthma and to increase the potential number of eligible participants for the ongoing Study 601-0018 of PUR1900 in subjects with ABPA. See: NCT05667662. Additionally, this prescreening study may provide information that could assist the conduct of future studies conducted by Pulmatrix.

NCT ID: NCT04108962 Withdrawn - Severe Asthma Clinical Trials

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

Start date: December 23, 2019
Phase: Phase 4
Study type: Interventional

Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

NCT ID: NCT03095547 Withdrawn - Clinical trials for Invasive Aspergillosis

Drug/Drug Interactions With F901318

Start date: May 2017
Phase: Phase 1
Study type: Interventional

Study of interactions between F901318 and multiple doses of posaconazole and pantoprazole and single doses of cyclosporine A and tacrolimus in healthy subjects. Pharmacokinetic (PK) profiles, safety and tolerability will be assessed.

NCT ID: NCT03076905 Withdrawn - Clinical trials for Invasive Aspergillosis

Pharmacokinetics of IV Formulation

Start date: May 2017
Phase: Phase 1
Study type: Interventional

Open label evaluation of a single intravenous dose of F901318 to healthy male and female subjects with pharmacokinetic and safety and tolerability evaluation.

NCT ID: NCT02912026 Withdrawn - Clinical trials for Invasive Aspergillosis

Radiolabelled IV and Oral Metabolism Study of F901318

ADME
Start date: May 2019
Phase: Phase 1
Study type: Interventional

Open label radiolabelled metabolism study of intravenous and oral solution forms of F901318. Five healthy male subjects will receive IV and five will receive an oral solution. Blood, urine and faeces will be collected over a period adequate to obtain 90% recovery of parent compound and to determine the metabolic profile of both IV and oral forms.

NCT ID: NCT02856178 Withdrawn - Clinical trials for Acute Myeloid Leukemia

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

SAFEGUARD
Start date: April 20, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This study assesses the pharmacokinetics and safety of the new antifungal F901318 in AML patients.

NCT ID: NCT01622595 Withdrawn - Aspergillosis Clinical Trials

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients

Start date: November 2009
Phase: N/A
Study type: Observational

OBSERVATIONAL STUDY OF INFECTIOUS COMPLICATIONS IN CANCER PATIENTS

NCT ID: NCT01207128 Withdrawn - Aspergillosis Clinical Trials

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the therapeutic effectiveness of combination antifungal therapy (CAT) of voriconazole plus micafungin versus voriconazole plus placebo equivalent as primary therapy for invasive aspergillosis (IA) in patients with hematological cancer.

NCT ID: NCT01188759 Withdrawn - Aspergillosis Clinical Trials

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

Start date: May 2012
Phase: Phase 3
Study type: Interventional

This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.

NCT ID: NCT00423163 Withdrawn - Clinical trials for Aspergillosis/Invasive

A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis

Start date: February 2007
Phase: Phase 4
Study type: Interventional

To evaluate the therapeutic effectiveness of voriconazole + micafungin versus voriconazole alone as primary therapy for invasive aspergillosis.